203 related articles for article (PubMed ID: 27127140)
21. Differential Susceptibility of Human Pleural and Peritoneal Mesothelial Cells to Asbestos Exposure.
Dragon J; Thompson J; MacPherson M; Shukla A
J Cell Biochem; 2015 Aug; 116(8):1540-52. PubMed ID: 25757056
[TBL] [Abstract][Full Text] [Related]
22. Identification of actionable mutations in malignant pleural mesothelioma.
Shukuya T; Serizawa M; Watanabe M; Akamatsu H; Abe M; Imai H; Tokito T; Ono A; Taira T; Kenmotsu H; Naito T; Murakami H; Takahashi T; Endo M; Ohde Y; Nakajima T; Yamamoto N; Koh Y
Lung Cancer; 2014 Oct; 86(1):35-40. PubMed ID: 25174276
[TBL] [Abstract][Full Text] [Related]
23. The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma.
Giroux Leprieur E; Hirata T; Mo M; Chen Z; Okamoto J; Clement G; Li H; Wislez M; Jablons DM; He B
Lung Cancer; 2014 Sep; 85(3):465-71. PubMed ID: 25023662
[TBL] [Abstract][Full Text] [Related]
24. An asbestos-exposed family with multiple cases of pleural malignant mesothelioma without inheritance of a predisposing BAP1 mutation.
Cheung M; Kadariya Y; Pei J; Talarchek J; Facciolo F; Visca P; Righi L; Cozzi I; Testa JR; Ascoli V
Cancer Genet; 2015 Oct; 208(10):502-7. PubMed ID: 26364129
[TBL] [Abstract][Full Text] [Related]
25. Establishment and mutation analysis of a novel malignant peritoneal mesothelioma cell line, TU-MM-1, using whole genome sequencing.
Oumi N; Itamochi H; Komatsu H; Oishi T; Shimada M; Sato S; Chikumi J; Sato S; Nonaka M; Kudoh A; Harada T
Hum Cell; 2016 Jan; 29(1):46-51. PubMed ID: 26070481
[TBL] [Abstract][Full Text] [Related]
26. Molecular Characterization of Peritoneal Mesotheliomas.
Offin M; Yang SR; Egger J; Jayakumaran G; Spencer RS; Lopardo J; Nash GM; Cercek A; Travis WD; Kris MG; Ladanyi M; Sauter JL; Zauderer MG
J Thorac Oncol; 2022 Mar; 17(3):455-460. PubMed ID: 34648949
[TBL] [Abstract][Full Text] [Related]
27. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
de Reyniès A; Jaurand MC; Renier A; Couchy G; Hysi I; Elarouci N; Galateau-Sallé F; Copin MC; Hofman P; Cazes A; Andujar P; Imbeaud S; Petel F; Pairon JC; Le Pimpec-Barthes F; Zucman-Rossi J; Jean D
Clin Cancer Res; 2014 Mar; 20(5):1323-34. PubMed ID: 24443521
[TBL] [Abstract][Full Text] [Related]
28. Genomic Landscape of Pleural Mesothelioma and Therapeutic Aftermaths.
Nash A; Creaney J
Curr Oncol Rep; 2023 Dec; 25(12):1515-1522. PubMed ID: 38015374
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases.
Rusch A; Ziltener G; Nackaerts K; Weder W; Stahel RA; Felley-Bosco E
Lung Cancer; 2015 Jan; 87(1):77-9. PubMed ID: 25468148
[TBL] [Abstract][Full Text] [Related]
30. Pediatric, Adolescent and Young Adult (AYA) Peritoneal and Pleural Mesothelioma: A National Cancer Database Review.
Nofi CP; Roberts BK; Rich BS; Glick RD
J Pediatr Surg; 2024 Jun; 59(6):1113-1120. PubMed ID: 38418273
[TBL] [Abstract][Full Text] [Related]
31. 50 Patients with Malignant Mesothelioma of Both the Pleura and Peritoneum: A Single-Institution Experience.
Letica-Kriegel AS; Leinwand JC; Sonett JR; Gorenstein LA; Taub RN; Chabot JA; Kluger MD
Ann Surg Oncol; 2020 Jan; 27(1):205-213. PubMed ID: 31065962
[TBL] [Abstract][Full Text] [Related]
32. A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma.
Lai J; Zhou Z; Tang XJ; Gao ZB; Zhou J; Chen SQ
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27187383
[TBL] [Abstract][Full Text] [Related]
33. Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas.
Kang HC; Kim HK; Lee S; Mendez P; Kim JW; Woodard G; Yoon JH; Jen KY; Fang LT; Jones K; Jablons DM; Kim IJ
Oncotarget; 2016 Feb; 7(7):8321-31. PubMed ID: 26824986
[TBL] [Abstract][Full Text] [Related]
34. Genomic characterization of malignant pleural mesothelioma and associated clinical outcomes.
Markowitz P; Patel M; Groisberg R; Aisner J; Jabbour SK; De S; Ganesan S; Malhotra J
Cancer Treat Res Commun; 2020; 25():100232. PubMed ID: 33166854
[TBL] [Abstract][Full Text] [Related]
35. Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations.
Sneddon S; Dick I; Lee YCG; Musk AWB; Patch AM; Pearson JV; Waddell N; Allcock RJN; Holt RA; Robinson BWS; Creaney J
Lung Cancer; 2018 May; 119():64-70. PubMed ID: 29656754
[TBL] [Abstract][Full Text] [Related]
36. Low homozygous/high heterozygous deletion status by p16 FISH correlates with a better prognostic group than high homozygous deletion status in malignant pleural mesothelioma.
Hamasaki M; Matsumoto S; Abe S; Hamatake D; Kamei T; Hiroshima K; Kawahara K; Sato A; Tsujimura T; Nakatani Y; Yoshida Y; Iwasaki A; Nabeshima K
Lung Cancer; 2016 Sep; 99():155-61. PubMed ID: 27565933
[TBL] [Abstract][Full Text] [Related]
37. Molecular alterations and potential actionable mutations in peritoneal mesothelioma: a scoping review of high-throughput sequencing studies.
Dietz MV; van Kooten JP; Paats MS; Aerts JGVJ; Verhoef C; Madsen EVE; Dubbink HJ; von der Thüsen JH
ESMO Open; 2023 Aug; 8(4):101600. PubMed ID: 37453150
[TBL] [Abstract][Full Text] [Related]
38. Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.
Bononi A; Napolitano A; Pass HI; Yang H; Carbone M
Expert Rev Respir Med; 2015 Oct; 9(5):633-54. PubMed ID: 26308799
[TBL] [Abstract][Full Text] [Related]
39. Epidermal growth factor receptor mutations in malignant pleural and peritoneal mesothelioma.
Enomoto Y; Kasai T; Takeda M; Takano M; Morita K; Kadota E; Iizuka N; Maruyama H; Haratake J; Kojima Y; Ikeda N; Inatsugi N; Nonomura A
J Clin Pathol; 2012 Jun; 65(6):522-7. PubMed ID: 22412050
[TBL] [Abstract][Full Text] [Related]
40. Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma.
Kalra N; Zhang J; Thomas A; Xi L; Cheung M; Talarchek J; Burkett S; Tsokos MG; Chen Y; Raffeld M; Miettinen M; Pastan I; Testa JR; Hassan R
BMC Cancer; 2015 May; 15():376. PubMed ID: 25952750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]